Itaconate: A Potential Therapeutic Strategy for Autoimmune Disease

Area of Science:

• Biochemistry
• Immunology
• Metabolomics

Background:

• Itaconate is an endogenous metabolite derived from the Krebs cycle.
• It possesses innate immune-modulating properties, inhibiting inflammatory cytokine production.
• Its initial known mechanism involved inhibiting succinate dehydrogenase (SDH).

Purpose of the Study:

• To explore the multifaceted mechanisms of itaconate's biological functions.
• To investigate its role in modulating immune cell activity and inflammatory responses.
• To assess its therapeutic potential in inflammatory and autoimmune diseases.

Main Methods:

• Investigated itaconate's interaction with cysteine residues via Michael addition.
• Examined its effects on the KEAP1-NRF2 signaling pathway.
• Analyzed its impact on glycolytic enzymes and other cellular factors.
• Studied its influence on immune cell function.

Main Results:

• Itaconate modifies proteins, including KEAP1, activating the NRF2 pathway.
• It exhibits antioxidant effects and attenuates inflammatory responses.
• It influences immune cell activity, suggesting therapeutic applications.
• Itaconate demonstrates a dual role in inhibiting inflammation and oxidative stress.

Conclusions:

• Itaconate's biological functions have been redefined beyond its initial industrial applications.
• Itaconate exhibits significant therapeutic potential for inflammatory and autoimmune conditions.
• Further research is required to elucidate its complete mechanism of action, diverse functions, and clinical applications.